All News
Filter News
Found 2,543 articles
-
Despite not having a single candidate in the clinical stage, the Moderna-backed biotech is offering 6.25 million shares for $15 apiece in an initial public offering. Shares are expected to begin trading Friday.
-
Takeda, AbbVie and Moderna are among the companies with open positions.
-
Novo’s Catalent Acquisition Surprises Some Analysts, Raises Questions about Existing Contracts
2/7/2024
While analysts are bullish on Novo Holdings’ $16.5 billion acquisition of Catalent, they say it raises questions for companies that have contracted the CDMO for manufacturing. -
Moderna Chief Executive Officer Stéphane Bancel Elected to National Academy of Engineering
2/7/2024
Moderna, Inc. announced that Stéphane Bancel, Chief Executive Officer, has been elected to the National Academy of Engineering, broadly known as one of the highest acknowledgments of achievement in the field, in recognition of distinguished contributions to engineering and the "development and manufacturing of pharmaceutical products, including the COVID-19 vaccine.".
-
Sail Biomedicines Appoints Kerry Benenato, Ph.D., as Chief Platform Officer
2/7/2024
Sail Biomedicines, Inc. (“Sail”), a Flagship Pioneering company and leader in RNA-based programmable medicines, today announced that Kerry Benenato, Ph.D., has been appointed to the position of the role of Chief Platform Officer, replacing Stuart Milstein, Ph.D., who is leaving the company to pursue other opportunities.
-
Metagenomi could potentially raise over $100 million if the underwriters exercise their option to purchase additional shares in full, assuming an initial public offering price of $16 per share.
-
Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
2/5/2024
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the fourth quarter and full year ended December 31, 2023 and provided full year 2024 financial guidance.
-
Merck Announces Fourth-Quarter and Full-Year 2023 Financial Results
2/1/2024
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2023.
-
Moderna to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024
2/1/2024
Moderna, Inc. (Nasdaq:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, February 22, 2024 to report its fourth quarter and full year 2023 financial results, and provide a corporate update.
-
The CEOs of J&J and Merck have finally committed to testifying before the Senate health committee regarding the high prices of drugs in the U.S. The hearing is set for Feb. 8.
-
The clinical development pipeline for vaccines is broad but shallow with a large proportion of programs dedicated to COVID-19, according to a new report by industry group Biotechnology Innovation Organization.
-
Ahead of a Jan. 31 vote, Senate health committee chair Sen. Bernie Sanders on Thursday said he has the votes needed to subpoena the CEOs of Johnson & Johnson and Merck to testify on drug pricing.
-
While the company expects sales growth to be flat this year, Lonza’s shares jumped around 14% Friday morning after reporting full-year 2023 sales of $7.75 billion, which was 3% above the consensus.
-
In the biopharma industry, engineers are pivotal drivers of innovation, helping to shape the landscape of healthcare discoveries.
-
WestGene Spearheads Oncology Breakthroughs at the 3rd mRNA-Based Therapeutics Summit
1/24/2024
Kicking off the New Year with remarkable achievements, Chengdu -based WestGene made a significant impact at the 3rd mRNA-Based Therapeutics Summit in Berlin, Germany.
-
CytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051, a Probody® Antibody Drug Conjugate (ADC) Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2b
1/24/2024
CytomX Therapeutics, Inc. today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) applications for the conditionally activated Probody® therapeutics CX-2051, an EpCAM-directed ADC, and CX-801, a dually-masked version of interferon-alpha 2b.
-
With initial public offering activity continuing to gain momentum in early 2024, ArriVent Biopharma in a Monday SEC filing laid out the company’s plans to go public.
-
The pharma execs may be served with subpoenas to appear before the Senate health committee to explain why their products are much more expensive in the U.S. than in other countries, according to chairman Sen. Bernie Sanders.
-
In a changing landscape, top companies are increasingly embracing remote work.
-
NextPoint Therapeutics Appoints Tatiana Novobrantseva, PhD, as Chief Scientific Officer
1/16/2024
NextPoint Therapeutics, a clinical-stage biotechnology company developing precision immuno-oncology therapeutics targeting the novel HHLA2 pathway, today announced the appointment of Tatiana Novobrantseva, PhD, as Chief Scientific Officer (CSO).